Major cardiovascular events recorded at diagnosis or during follow-up according to the JAK2 617V>F mutational state
| . | Polycythemia vera, n = 323 . | Essential thrombocythemia, n = 639 . | |||
|---|---|---|---|---|---|
| Hetero . | Homo . | WT . | Hetero . | Homo . | |
| Patients, no. (%) | 219 (67.8) | 104 (32.2) | 257 (40.2) | 368 (57.6) | 14 (2.2) |
| Patients with cardiovascular events at diagnosis, no. (%) | |||||
| Total | 46 (21.0) | 16 (15.4) | 27 (10.5)* | 80 (21.7)* | 7 (50.0) |
| Arterial events | 36 (16.4) | 13 (12.5) | 14 (5.5) | 52 (14.1) | 2 (14.3) |
| Venous events | 14 (6.4) | 3 (2.9) | 12 (4.7)* | 29 (7.9)* | 5 (35.7) |
| Patients with cardiovascular events during follow-up | |||||
| Total, no. (%) | 29 (13.2) | 19 (18.3) | 23 (9.0)* | 45 (12.2)* | 6 (42.9) |
| Time to first thrombosis, person-year | 1034 | 739 | 1739 | 2122 | 78 |
| Incidence rate, × 100 | 2.8 | 2.6 | 1.3 | 2.1 | 7.7 |
| Arterial events, no. (%) | 22 (10.1) | 13 (12.5) | 15 (5.8)* | 23 (6.3)* | 4 (28.6) |
| Venous events, no. (%) | 9 (4.1) | 8 (7.7) | 7 (2.7)* | 23 (6.3)* | 3 (21.4) |
| . | Polycythemia vera, n = 323 . | Essential thrombocythemia, n = 639 . | |||
|---|---|---|---|---|---|
| Hetero . | Homo . | WT . | Hetero . | Homo . | |
| Patients, no. (%) | 219 (67.8) | 104 (32.2) | 257 (40.2) | 368 (57.6) | 14 (2.2) |
| Patients with cardiovascular events at diagnosis, no. (%) | |||||
| Total | 46 (21.0) | 16 (15.4) | 27 (10.5)* | 80 (21.7)* | 7 (50.0) |
| Arterial events | 36 (16.4) | 13 (12.5) | 14 (5.5) | 52 (14.1) | 2 (14.3) |
| Venous events | 14 (6.4) | 3 (2.9) | 12 (4.7)* | 29 (7.9)* | 5 (35.7) |
| Patients with cardiovascular events during follow-up | |||||
| Total, no. (%) | 29 (13.2) | 19 (18.3) | 23 (9.0)* | 45 (12.2)* | 6 (42.9) |
| Time to first thrombosis, person-year | 1034 | 739 | 1739 | 2122 | 78 |
| Incidence rate, × 100 | 2.8 | 2.6 | 1.3 | 2.1 | 7.7 |
| Arterial events, no. (%) | 22 (10.1) | 13 (12.5) | 15 (5.8)* | 23 (6.3)* | 4 (28.6) |
| Venous events, no. (%) | 9 (4.1) | 8 (7.7) | 7 (2.7)* | 23 (6.3)* | 3 (21.4) |
P < .05 in the comparison of homozygous patients to either wild-type (in case of ET) or a heterozygous counterpart.